Physician profile
Christopher Weeden
NPI 1538628482
$8,784.79
in general payments reported to CMS, 2019-2025
11 companies · $4,129 in 2025
The $4,129 reported for 2025 was more than what 89% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,000 · 2024: $3,656 · 2025: $4,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,338 · Travel and Lodging: $2,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,338.30 |
| Travel and Lodging | $2,446.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,914.96 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Spinal Simplicity, LLC | $1,904.55 | 2024-2025 | Ha Minuteman G3-R, Liberty Si |
| Medtronic, INC. | $1,303.04 | 2023-2024 | Vanta Adaptivestim, Intellis Adaptivestim, Accurian |
| Abbott Laboratories | $420.24 | 2024 | Proclaim, Eterna |
| Mml US, INC. | $294.34 | 2024-2025 | Reactiv8 |
| Saluda Medical Americas, INC. | $286.70 | 2024-2025 | Evoke |
| Averitas Pharma INC. | $269.61 | 2024 | Qutenza |
| Curonix LLC | $180.00 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biotronik Nro, INC. | $152.77 | 2024 | Prospera |
| Stryker Corporation | $36.56 | 2025 | Mild Device Kit |
| Globus Medical, INC. | $22.02 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Weeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.